LEO Pharma A/S, a global leader in medical dermatology, is pleased to share that The Lancet, which is considered one of the ...

More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with moderate to severe chronic hand eczema ...

Delgocitinib cream is efficacious and well-tolerated for the treatment of adults with chronic hand eczema for up to 52 weeks.

Treatment with delgocitinib cream, a topical pan-Janus kinase inhibitor, resulted in a significant improvement in health-related quality of life in patients with moderate to severe chronic hand ...

Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.

Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE. It inhibits the activation of JAK-STAT signaling, which plays a key role in the ...

drug delgocitinib, saying it outperformed the only approved drug therapy for the condition in a phase 3 trial. LEO’s topical cream formulation of the pan-JAK inhibitor proved to be more ...

the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib) comes after the European Commission approved the drug last ...

symptoms of moderate to severe frontal fibrosing alopecia improved with topical delgocitinib. Medscape Medical News, October 02, 2024 Avoiding Common Diagnostic Errors in Primary Care Experts on ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 LEO Pharma A/S, a global leader in medical ...